Ann: DEP irinotecan clinical data presented at AACR meeting, page-16

Not even half way through the trading day and over 550,000 shares dumped already (again at record lows) would suggest some just aren't convinced about the 4 separate DEP® irinotecan ASX announcements released by JF & Co. in the last 34 days ... I guess it is either that or perhaps the past performance of this mob - take your pick I guess ?


@sarge17 - yes I also found those comments about 'not wanting a DEP® deal at these low share prices' laughable ... you know the very licensing deal(s) LT shareholders have been waiting years for Starpharma to secure ?